HB-1
Phase 2Small molecule
HB-1 is one of 33 small molecule programs targeting Panic Disorder. It is currently in Phase 2.
2
Indications
2
Total Trials
2
Active Trials
32
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
41 competitors in Panic Disorder
#DrugCompanyPhaseTrials
1Atarax
PfizerApproved
Paxil CR
GSKApproved
Brintellix
TakedaApproved
Cymbalta
Alnylam PharmaceuticalsApproved
Paxil
SSebela Pharmaceuticals Development LLC
Approved
Lexapro
AbbVieApproved
Xanax
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Celexa
AbbVieApproved
Klonopin
EEngelhard Arzneimittel GmbH & Co.KG
Approved
Zoloft
VViatris Specialty LLC
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for HB-1. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- HHoneybrains Biotech LLC